Intervention

diagnostic laboratory biomarker analysis

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21

Recruiting0

Common conditions25

Lead sponsors shown15

Clinical trials

21 shown

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionNCT01249443 · 2013-11-01

Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32NCT01666171 · 2012-08-01

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerNCT01282333 · 2011-01-01

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast CancerNCT01208441 · 2010-11-01

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by SurgeryNCT01234532 · 2010-10-01

Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal SyndromeNCT00938756 · 2008-04-01

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing SurgeryNCT00977457 · 2007-11-26

ACTIVE_NOT_RECRUITING

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2NCT00544804 · 2007-08-01

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to TherapyNCT00509691 · 2007-06-01

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung CancerNCT00897533 · 2007-04-13

Bicalutamide in Treating Patients With Metastatic Breast CancerNCT00468715 · 2007-03-23

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast CancerNCT00516425 · 2007-01-01

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and FluorouracilNCT00897091 · 2006-07-01

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17NCT00897065 · 2006-06-01

Changes in DNA After Radiation Therapy in Patients With Prostate CancerNCT00899912 · 2006-06-01

HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598NCT00896909 · 2006-02-02

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate CancerNCT00379119 · 2005-01-01

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCISNCT00324714 · 2003-02-01

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast DiseaseNCT00813878 · 2001-07-01

Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831NCT00898898 · 2000-05-01

Common conditions

Breast Cancer10 HER2-negative Breast Cancer3 Prostate Cancer3 Stage IV Non-small Cell Lung Cancer3 Advanced Adult Primary Liver Cancer2 Estrogen Receptor-negative Breast Cancer2 Lung Cancer2 Metastatic Cancer2 Progesterone Receptor-negative Breast Cancer2 Recurrent Anal Cancer2 Recurrent Breast Cancer2 Recurrent Esophageal Cancer2 Recurrent Gastric Cancer2 Recurrent Metastatic Squamous Neck Cancer With Occult Primary2 Recurrent Non-small Cell Lung Cancer2 Recurrent Ovarian Epithelial Cancer2 Recurrent Salivary Gland Cancer2 Recurrent Squamous Cell Carcinoma of the Hypopharynx2 Recurrent Squamous Cell Carcinoma of the Larynx2 Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity2 Recurrent Squamous Cell Carcinoma of the Nasopharynx2 Recurrent Squamous Cell Carcinoma of the Oropharynx2 Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity2 Recurrent Verrucous Carcinoma of the Larynx2 Recurrent Verrucous Carcinoma of the Oral Cavity2

Leading sponsors

National Cancer Institute (NCI) 3 City of Hope Medical Center 2 ECOG-ACRIN Cancer Research Group 2 University of California, San Francisco 2 AIDS Malignancy Consortium 1 Alliance for Clinical Trials in Oncology 1 Cancer and Leukemia Group B 1 Centre Oscar Lambret 1 Charing Cross Hospital 1 ETOP IBCSG Partners Foundation 1 Massachusetts General Hospital 1 Memorial Sloan Kettering Cancer Center 1 Radiation Therapy Oncology Group 1 SWOG Cancer Research Network 1 University of Louisville 1

Trial status mix

COMPLETED9

TERMINATED6

UNKNOWN4

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE17

PHASE22

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.